Ironwood Pharmaceuticals Inc (IRWD): Halley E Gilbert , Chief Legal Officer of Ironwood Pharmaceuticals Inc sold 20,275 shares on May 25, 2016. The Insider selling transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were sold at $12.19 per share for a total value of $247,152.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 11, 2016, Peter M Hecht (Chief Executive Officer) sold 120,000 shares at $10.72 per share price.On Mar 11, 2016, Mark G Currie (Chief Scientific Officer) sold 150,000 shares at $10.86 per share price.Also, On Mar 9, 2016, Lawrence S Olanoff (director) sold 2,200 shares at $11.11 per share price.On Feb 26, 2016, Thomas Graney (Chief Financial Officer) sold 563 shares at $8.50 per share price.
Ironwood Pharmaceuticals: On Wednesday, May 25, 2016 heightened volatility was witnessed in Ironwood Pharmaceuticals which led to swings in the share price. The shares opened for trading at $12.1 and hit $12.4 on the upside , eventually ending the session at $12.27, with a gain of 1.74% or 0.21 points. The heightened volatility saw the trading volume jump to 17,30,830 shares. The 52-week high of the share price is $14.28 and the company has a market cap of $1,774 M . The 52-week low of the share price is at $7.35.
Company has been under the radar of several Street Analysts.Ironwood Pharmaceuticals is Reiterated by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 16 from a previous price target of $15 .The Rating was issued on May 10, 2016.Ironwood Pharmaceuticals is Reiterated by Wedbush to Neutral and the brokerage firm has raised the Price Target to $ 10 from a previous price target of $9 .The Rating was issued on Apr 28, 2016.Ironwood Pharmaceuticals is Initiated by Goldman to Neutral. The Rating was issued on Mar 21, 2016.
Ironwood Pharmaceuticals Inc. is a pharmaceutical company. The Company has a product linaclotide which is available in the United States and Mexico under the brand name LINZESS and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.